IHCH-3064

IHCH-3064 is a dual-acting compounds targeting Adenosine A2A Receptor and HDAC. IHCH-3064 exhibits potent binding to A2AR (Ki=2.2 nM) and selective inhibition of HDAC1 (IC50=80.2 nM), with good antiproliferative activity against tumor cell lines in vitro. IHCH-3064 is a tumor immunotherapeutic agent.

Product Specifications

CAS Number

[2420562-65-6]

UNSPSC

12352005

Target

Adenosine Receptor; HDAC

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; GPCR/G Protein

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ihch-3064.html

Solubility

10 mM in DMSO

Smiles

O=C(C1=CC=C(CCN2N=CC3=C2N=C(N)N4N=C(C5=CC=CO5)N=C34)C=C1)NC6=C(N)C=CC=C6

Molecular Formula

C25H21N9O2

Molecular Weight

479.49

References & Citations

[1]Wenzhong Yan, et al. Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A 2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents. J Med Chem. 2021 Nov 25;64 (22) :16573-16597.